Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Accessing the accelerated approval pathway for rare disease therapeutics

Improvements must be made to the qualification process for biomarkers as primary endpoints in pivotal clinical studies of treatments for the rarest of diseases.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1


  1. 1

    FDA. Accelerated approvals. (accessed 31 December 2014 and 31 December 2015).

  2. 2

    Kakkis, E.D. et al. Orphanet J. Rare Dis. 10, 16 (2015).

    Article  Google Scholar 

  3. 3

    Miyamoto, B.E. & Kakkis, E.D. Orphanet J. Rare Dis. 6, 49 (2011).

    Article  Google Scholar 

  4. 4

    US Food and Drug Administration. Center for Drug Evaluation and Research. Guidance for Industry. Expedited Programs for Serious Conditions-Drugs and Biologics. (FDA, Washington, DC, 2014). (accessed 7 July and 23 August 2014).

  5. 5

    Sasinowski, F.J. Drug Info. J. 46, 238 (2012).

    Article  Google Scholar 

  6. 6

    FDA. New drugs at FDA: CDER's new molecular entities and new therapeutic biological products. (accessed July 7, 2014 and January 15, 2015).

  7. 7

    Waisbren, S.E. et al. Mol. Genet. Metab. 92, 63–70 (2007).

    CAS  Article  Google Scholar 

  8. 8

    Food and Drug Administration Safety and Innovation Act (FDASIA), Pub. L. 112–144, 126 Stat. 993, codified as amended at 21 U.S.C. §301 (2012).

  9. 9

    FDA. Rare Diseases: Common Issues in Drug Development Guidance for Industry. (accessed January 18 2015).

Download references

Author information



Corresponding author

Correspondence to Emil D Kakkis.

Ethics declarations

Competing interests

E.K. is a current employee of and stockholder in Ultragenyx, a stockholder in BioMarin and president of the EveryLife Foundation for Rare Diseases.

Supplementary information

Supplementary Information

Supplementary Tables 1 and 2 (DOCX 48 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kakkis, E., Kowalcyk, S. & Bronstein, M. Accessing the accelerated approval pathway for rare disease therapeutics. Nat Biotechnol 34, 380–383 (2016).

Download citation


Quick links